International Menopause Society sets new global standards for menopause care with evidence-led framework For the first time in a decade, the International Menopause Society (IMS) has released a complete redevelopment of its global menopause recommendations. Grounded...
An RNA therapy that preserves muscle while cutting visceral fat, a first in class oral non incretin obesity pill, late stage lung cancer portfolio data, NK cell immunotherapy in Alzheimer’s disease, and the first human trial of a cellular rejuvenation medicine...
This week brought a remarkable series of clinical trial readouts spanning oncology, metabolic disease, neurology, and dermatology. Several pivotal datasets were released from late-stage and early-stage programmes, offering fresh hope for patients with conditions...
We work with hospitals, clinics, and health systems across the country every day. Over the past few years, one thing has become very clear: filling a specialist role is harder than it used to be, it takes longer, and the consequences of getting it wrong reach further...
Drug development is one of the most expensive and time-intensive innovation processes in the world. Estimates from the Tufts Center for the Study of Drug Development suggest that bringing a new drug to market can cost over $2.6 billion and take more than a decade of...
Medication non-adherence and dropout have long been labeled “known problems” in the clinical trial space. Yet despite years of tinkering with the formula, these challenges have only become “well-known problems.” Operational efficiencies and innovation, digital...
Medication non-adherence and dropout have long been labeled “known problems” in the clinical trial space. Yet despite years of tinkering with the formula, these challenges have only become “well-known problems.” Operational efficiencies and innovation, digital...
At the 2026 Congress of the European Society of Gynaecological Oncology (ESGO) in Copenhagen, Dr Gabriel Levin of the McGill University Health Centre will present Phase II data evaluating the investigational DNA therapy Elenagen in combination with gemcitabine for...
Dr Steven Cox, CEO of the research charity, Cardiac Risk in the Young (CRY) explains the key findings and importance of a seminal study (reviewing cardiac screening data collated over a 10 year period), published on 24 February 2026 in the Journal of the American...
Couples trying to conceive are bombarded with supplement recommendations. Scroll through any fertility forum and you'll find confident claims about CoQ10, vitamin D, and a dozen other compounds that supposedly hold the key to conception. Some of these recommendations...
Wouldn’t life be easier if someone was there to keep on top of chores around the house? That’s the idea behind Anavex Life Sciences’ experimental, once-daily pill blarcamesine, which is being tested in patients in the early stages of Alzheimer’s disease. This drug...
The next operational lessons for early-stage clinical trials in humans might not come from pharma but from a cattle ranch in Nebraska. While human clinical research debates decentralized trials, adaptive protocols, novel technologies, and new approaches to oversight,...
New research suggests that inflammatory and microstructural changes in a key brain reward region may differ between chronic depression and acute depressive symptoms, offering fresh insight into the biological mechanisms underlying the condition. In a large scale...
The Functional Gut Clinic (FGC), the UK’s leading provider of specialist gastrointestinal (GI) diagnostics, today announced the launch of its dedicated GI Clinical Trials establishing the organisation as the country’s first boutique, end‑to‑end clinical research...
Pharvaris Announces Positive Phase 3 Results for Deucrictibant as On Demand HAE Treatment Pharvaris has announced positive topline data from its global Phase 3 RAPIDe 3 study, confirming that the oral bradykinin B2 receptor antagonist deucrictibant shows strong...
Otsuka Gains Approval for First of Its Kind Treatment Against Rare Kidney Disease In a significant milestone for kidney disease care, Otsuka Pharmaceutical has received accelerated approval from the US Food and Drug Administration for a new therapy for Immunoglobulin...
Engasertib Trial Offers New Hope for Patients with Hereditary Hemorrhagic Telangiectasia A recent clinical study has delivered encouraging results for people living with hereditary hemorrhagic telangiectasia, a rare genetic vascular disorder that causes chronic and...
Pharmaceutical approaches to ALS remain sparse and "hard-to-develop". Riluzole (approved 1995) and edaravone (IV in 2017, oral in 2022) only offer modest benefits. More recently, Biogen's Qalsody (tofersen) was approved for SOD1-mutant ALS. But a new wave of new...